```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5353 Introduced in House (IH)]

<DOC>

115th CONGRESS
  2d Session
                                H. R. 5353

  To amend the Public Health Service Act to reauthorize and expand a 
 program of surveillance and education, carried out by the Centers for 
 Disease Control and Prevention, regarding infections associated with 
                          injection drug use.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 20, 2018

   Mr. Lance (for himself, Mr. Kennedy, Mr. Collins of New York, Ms. 
Eshoo, Mr. Barton, and Ms. Matsui) introduced the following bill; which 
          was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
  To amend the Public Health Service Act to reauthorize and expand a 
 program of surveillance and education, carried out by the Centers for 
 Disease Control and Prevention, regarding infections associated with 
                          injection drug use.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Eliminating Opioid Related 
Infectious Diseases Act of 2018''.

SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM OF SURVEILLANCE AND 
              EDUCATION REGARDING INFECTIONS ASSOCIATED WITH INJECTION 
              DRUG USE.

    Section 317N of the Public Health Service Act (42 U.S.C. 247b-15) 
is amended to read as follows:

``SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING INFECTIONS ASSOCIATED 
              WITH INJECTION DRUG USE.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, may (directly and 
through grants to public and nonprofit private entities) provide for 
programs to carry out the following activities:
            ``(1) To cooperate with the States in implementing a 
        surveillance system to determine the incidence of infections 
        associated with injection drug use and to assist the States in 
        determining the prevalence of such infections, including the 
        reporting of chronic hepatitis C virus and human 
        immunodeficiency virus cases.
            ``(2) To identify, counsel, and offer testing to 
        individuals who are at risk of infections as a result of 
        injection drug use, receiving blood transfusions prior to July 
        1992, or other risk factors.
            ``(3) To provide appropriate referrals for counseling, 
        testing, and medical treatment of individuals identified under 
        paragraph (2) and to ensure, to the extent practicable, the 
        provision of appropriate follow-up services.
            ``(4) To develop and disseminate public information and 
        education programs for the detection and control of infections 
        associated with injection drug use, with priority given to 
        high-risk populations as determined by the Secretary.
            ``(5) To improve the education, training, and skills of 
        health professionals in the detection and control of infections 
        associated with injection drug use, with priority given to 
        substance use disorder treatment providers, pediatricians, 
        other primary care providers, and obstetrician-gynecologists.
    ``(b) Laboratory Procedures.--The Secretary may (directly and 
through grants to public and nonprofit private entities) carry out 
programs to provide for improvements in the quality of clinical-
laboratory procedures regarding infections associated with injection 
drug use.
    ``(c) Definitions.--In this section, the term `injection drug use' 
means--
            ``(1) intravenous administration of a substance in schedule 
        I under section 202 of the Controlled Substances Act;
            ``(2) intravenous administration of a substance in schedule 
        II, III, IV, or V under section 202 of the Controlled 
        Substances Act that has not been approved for intravenous use 
        under--
                    ``(A) section 505 of the Federal Food, Drug and 
                Cosmetic Act; or
                    ``(B) section 351 of the Public Health Service Act; 
                or
            ``(3) intravenous administration of a substance in schedule 
        II, III, IV, or V under section 202 of the Controlled 
        Substances Act that has not been prescribed to the person using 
        the substance.
    ``(d) Authorization of Appropriations.--For the purpose of carrying 
out this section, there are authorized to be appropriated $40,000,000 
for each of the fiscal years 2019 through 2023.''.
                                 <all>
```